Clincosm LogoSign in Get a demo

Real-Time MV/kV Image Guided Radiation Therapy

Sponsor
Stanford University (Other)
Overall Status
Withdrawn
CT.gov ID
NCT01260909
Collaborator
National Institutes of Health (NIH) (NIH), National Cancer Institute (NCI) (NIH)
0
Enrollment
12
Duration (Months)

Study Details

Study Description

Brief Summary

In current radiation therapy, imaging (typically, cone beam CT imaging or two orthogonal X-ray projection imaging) is done for patient setup before radiation dose delivery. Dose delivery typically takes 2 to 5 minutes depending on the delivery technique used for treatment. A tumor target may change its position during the dose delivery process. The goal of this project is develop a real-time imaging strategy to monitor the tumor position during dose delivery and evaluate its potential clinical impact.

Condition or Disease Intervention/Treatment Phase
  • Device: Real-time kV/MV Prostate Imaging

Study Design

Study Type:
Observational
Actual Enrollment :
0 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Real-Time MV/kV Image Guided Radiation Therapy
Study Start Date :
Jan 1, 2014
Anticipated Primary Completion Date :
Jan 1, 2015
Anticipated Study Completion Date :
Jan 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Real-time kV/MV Prostate Imaging

Device: Real-time kV/MV Prostate Imaging
The kV images will be acquired using onboard kV X-Ray imaging system existing in the clinical linear accelerator (LINAC).
Other Names:
  • Image-guided radiation therapy
  • External beam radiotherapy

    		•

    Outcome Measures

    Primary Outcome Measures

    1. To verify improved tumor targeting accuracy using IMRT (intensity modulated radiation therapy) and VMAT (volumetric modulated radiation therapy) [2 years]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • The study population will be drawn from available patient population that will be treated using IMRT/VMAT. The Stanford population of IMRT/VMAT will be taken as roughly representative of prospective IMRT patients and will not be subdivided by any additional characteristics.
    Exclusion Criteria:
    • The study population will be drawn from available patient population that will be treated using IMRT/VMAT. The Stanford population of IMRT/VMAT will be taken as roughly representative of prospective IMRT patients and will not be subdivided by any additional characteristics.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Stanford University
    • National Institutes of Health (NIH)
    • National Cancer Institute (NCI)

    Investigators

    • Principal Investigator: Lei Xing, Stanford University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Stanford University
    ClinicalTrials.gov Identifier:
    NCT01260909
    Other Study ID Numbers:
    • PROS0038
    • SU-12132010-7282
    • R21CA153587
    First Posted:
    Dec 15, 2010
    Last Update Posted:
    Dec 2, 2017
    Last Verified:
    Nov 1, 2017
    Additional relevant MeSH terms:
    Prostatic Neoplasms

    Study Results

    No Results Posted as of Dec 2, 2017